OPTUNEINFORMATION

Click here to go to the "Official" Optune™ Website

The safety profile of Tumor Treating Fields (TTFields) therapy in glioblastoma patients with ventriculoperitoneal shunts
This study shows that it is ok to use Optune when you have a shunt!

Updated 2-THE-TOP Data Suggest Improvements in Progression-Free Survival, Overall Survival Compared to Matched-Control Patients from EF-14 Trial
Reports amazing increases in survival by adding Keytruda to Optune.(Added 3/30/22)

Efficacy and Safety of Tumor Treating Fields (TTFields) in Elderly Patients with Newly Diagnosed Glioblastoma: Subgroup Analysis of the Phase 3 EF-14 Clinical Trial
For elderly patients, 15% 5 year survival in Optune group compared to 0% in control group.(Added 10/26/2021)

New Data Finds Tumor Treating Fields Initiates Downstream Anti-Tumor Response (added 2/25/2022)
This shows that Optune may enhance the effect of checkpoint inhibitors!

Long term followup on original Optune clinical trial
an astounding 20% survival at 15 years (in a small trial). Added 11/23/2020

High compliance with Optune™ linked to greatest survival benefit for glioblastoma
29% 5 year survival in high compliance group compared to 4.5% in control group.(Added 1/26/19)

Prevention and Management of Dermatologic Adverse Events Associated With Tumor Treating Fields in Patients With Glioblastoma
Read this if you are going to use Optune™ - it will help prevent the most comon problems.

No Unexpected Safety Issues Arise With Tumor Treating Fields in Glioblastoma Patients With Shunts, Pacemakers or Defibrillators
(Added 11/21/17)

Results from the trial for newly diagnoes GBM:
5 year survival rate more than doubles the standard of care! (added 9/24/17)

Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs. Temozolomide Alone for Glioblastoma
This may become the new standard of care for Glioblastoma multiforme. (added 12/15/15)

FDA Approves Optune for Newly Diagnosed Glioblastoma Patients.
Risk of death reduced by 37%!

Novocure (NVCR) Issues Positive Update on TTFields Study in Certain Glioblastoma Patients
Optune can now be used even if you have a non programmable shunt

New data on how Tumor Treating Fields Works

The name of the treatment has been changed from Novocure TTF100-A to Optune™ on 11/14/2014

Optune™ is a unique new form of treatment for brain tumors: it uses Tumor Treating Fields (TTF) to kill dividing cells. These fields are delivered by removable transducer arrays that are placed on the head. This was approved by the United States FDA in 2011 for use in patients with recurrent glioblastoma multiforme and in 2015 for use in patients with newly diagnosed glioblastoma multifore Tumor Treating Fields have been added to the NCCN guidelines as the standard of care for treatment of recurrent glioblastom multiform. See http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf (free registration is required). Click here for a news video about the Novocure NovoTTF-100A. Click on the links below for more information on Optune™. Educational videos Open Houses [Link to Optune.com list of open houses: Opens in new window] Find a Doctor who uses Optune™ Frequently Asked Questions Scientific articles about Optune™ News articles and press releases about the Optune™ system Financial Resources Online support group for people interested in Optune™ The Optune™ trial details on Clinical Trials.gov The Optune™ Patient Website The "Official" Novocure company Website Disclosure: the Novocure company is a sponsor of our organization.